p.88 抽出テキスト

Circulation. 2018;138:e272–e391. DOI: 10.1161/CIR.0000000000000549 September 25, 2018 e359 CLINICAL STATEMENTS AND GUIDELINES

S4.2.1-8.	 Buxton AE, Sweeney MO, Wathen MS, et al. QRS duration does not predict occurrence of ventricular tachyarrhythmias in patients with implanted cardioverter-defibrillators. J Am Coll Cardiol. 2005;46:310–6. S4.2.1-9.	 Desai AD, Yaw TS, Yamazaki T, et al. Prognostic significance of quantitative QRS duration. Am J Med. 2006;119:600–6. S4.2.1-10.	Dhar R, Alsheikh-Ali AA, Estes NA 3rd, et al. Association of prolonged QRS duration with ventricular tachyarrhythmias and sudden cardiac death in the Multicenter Automatic Defibrillator Implantation Trial II (MADIT-II). Heart Rhythm. 2008;5:807–13. S4.2.1-11.	Freedman RA, Alderman EL, Sheffield LT, et al. Bundle branch block in patients with chronic coronary artery disease: angiographic correlates and prognostic significance. J Am Coll Cardiol. 1987;10:73–80. S4.2.1-12.	Iuliano S, Fisher SG, Karasik PE, et al. QRS duration and mortality in patients with congestive heart failure. Am Heart J. 2002;143:1085–91. S4.2.1-13.	Kadish A, Dyer A, Daubert JP, et al. Prophylactic defibrillator implantation in patients with nonischemic dilated cardiomyopathy. N Engl J Med. 2004;350:2151–8. S4.2.1-14.	Zimetbaum PJ, Buxton AE, Batsford W, et al. Electrocardiographic predictors of arrhythmic death and total mortality in the multicenter unsustained tachycardia trial. Circulation. 2004;110:766–9. S4.2.1-15.	Costantini O, Hohnloser SH, Kirk MM, et al. The ABCD (Alternans Before Cardioverter Defibrillator) Trial: strategies using T-wave alternans to improve efficiency of sudden cardiac death prevention. J Am Coll Cardiol. 2009;53:471–9. S4.2.1-16.	Monasterio V, Martinez JP, Laguna P, et al. Prognostic value of average T-wave alternans and QT variability for cardiac events in MADIT-II patients. J Electrocardiol. 2013;46:480–6. S4.2.1-17.	Chow T, Kereiakes DJ, Onufer J, et al. Does microvolt T-wave alternans testing predict ventricular tachyarrhythmias in patients with ischemic cardiomyopathy and prophylactic defibrillators? The MASTER (Microvolt T Wave Alternans Testing for Risk Stratification of Post-Myocardial Infarction Patients) trial. J Am Coll Cardiol. 2008;52:1607–15. S4.2.1-18.	Gupta A, Hoang DD, Karliner L, et al. Ability of microvolt T-wave alternans to modify risk assessment of ventricular tachyarrhythmic events: a meta-analysis. Am Heart J. 2012;163:354–64. S4.2.1-19.	Bloomfield DM, Steinman RC, Namerow PB, et al. Microvolt T-wave

alternans distinguishes between patients likely and patients not likely to benefit from implanted cardiac defibrillator therapy: a solution to the Multicenter Automatic Defibrillator Implantation Trial (MADIT) II conundrum. Circulation. 2004;110:1885–9.

4.2.2 Ambulatory Electrocardiography

S4.2.2-1.	 Barrett PM, Komatireddy R, Haaser S, et al. Comparison of 24-hour Holter monitoring with 14-day novel adhesive patch electrocardiographic monitoring. Am J Med. 2014;127:95–7. S4.2.2-2.	 de Asmundis C, Conte G, Sieira J, et al. Comparison of the patientactivated event recording system vs. traditional 24 h Holter electrocardiography in individuals with paroxysmal palpitations or dizziness. Europace. 2014;16:1231–5. S4.2.2-3.	 Linzer M, Pritchett EL, Pontinen M, et al. Incremental diagnostic yield of loop electrocardiographic recorders in unexplained syncope. Am J Cardiol. 1990;66:214–9. S4.2.2-4.	 Turakhia MP, Hoang DD, Zimetbaum P, et al. Diagnostic utility

of a novel leadless arrhythmia monitoring device. Am J Cardiol. 2013;112:520–4.

4.2.3 Implanted Cardiac Monitors

S4.2.3-1.	 Bloch Thomsen PE, Jons C, Raatikainen MJ, et al. Long-term recording of cardiac arrhythmias with an implantable cardiac monitor in patients with reduced ejection fraction after acute myocardial infarction: the Cardiac Arrhythmias and Risk Stratification After Acute Myocardial Infarction (CARISMA) study. Circulation. 2010;122:1258–64. S4.2.3-2.	 Krahn AD, Klein GJ, Yee R, et al. Use of an extended monitoring strategy in patients with problematic syncope. Reveal Investigators. Circulation. 1999;99:406–10. S4.2.3-3.	 Solbiati M, Costantino G, Casazza G, et al. Implantable loop recorder versus conventional diagnostic workup for unexplained recurrent syncope. Cochrane Database Syst. Rev. 2016;4:CD011637. S4.2.3-4.	 Volosin K, Stadler RW, Wyszynski R, et al. Tachycardia detection

performance of implantable loop recorders: results from a large ‘real-life’ patient cohort and patients with induced ventricular arrhythmias. Europace. 2013;15:1215–22. S4.2.3-5.	 Linzer M, Pritchett EL, Pontinen M, et al. Incremental diagnostic

yield of loop electrocardiographic recorders in unexplained syncope. Am J Cardiol. 1990;66:214–9. S4.2.3-6.	 Turakhia MP, Hoang DD, Zimetbaum P, et al. Diagnostic utility

of a novel leadless arrhythmia monitoring device. Am J Cardiol. 2013;112:520–4.

4.2.4 Noninvasive Cardiac Imaging

S4.2.4-1.	 Solomon SD, Zelenkofske S, McMurray JJ, et al. Sudden death in patients with myocardial infarction and left ventricular dysfunction, heart failure, or both. N Engl J Med. 2005;352:2581–8. S4.2.4-2.	 Gula LJ, Klein GJ, Hellkamp AS, et al. Ejection fraction assessment and survival: an analysis of the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT). Am Heart J. 2008;156:1196–200. S4.2.4-3.	 Rauch B, Schiele R, Schneider S, et al. OMEGA, a randomized, placebo-controlled trial to test the effect of highly purified omega-3 fatty acids on top of modern guideline-adjusted therapy after myocardial infarction. Circulation. 2010;122:2152–9. S4.2.4-4.	 Shen WK, Sheldon RS, Benditt DG, et al. 2017 ACC/AHA/HRS guideline for the evaluation and management of patients with syncope: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. Circulation. 2017;136:e60–122. S4.2.4-5.	 Coleman GC, Shaw PW, Balfour PC Jr, et al. Prognostic value of myocardial scarring on CMR in patients with cardiac sarcoidosis: a systematic review and meta-analysis. JACC Cardiovasc Imaging. 2016;10:411–20. S4.2.4-6.	 Di Marco A, Anguera I, Schmitt M, et al. Late gadolinium enhancement and the risk for ventricular arrhythmias or sudden death in dilated cardiomyopathy: systematic review and meta-analysis. JACC Heart Fail. 2017;5:28–38. S4.2.4-7.	 Greulich S, Deluigi CC, Gloekler S, et al. CMR imaging predicts death and other adverse events in suspected cardiac sarcoidosis. JACC Cardiovasc Imaging. 2013;6:501–11. S4.2.4-8.	 Piers SR, Tao Q, van Huls van Taxis CF, et al. Contrast-enhanced MRI-derived scar patterns and associated ventricular tachycardias in nonischemic cardiomyopathy: implications for the ablation strategy. Circ Arrhythm Electrophysiol. 2013;6:875–83. S4.2.4-9.	 White JA, Fine NM, Gula L, et al. Utility of cardiovascular magnetic

resonance in identifying substrate for malignant ventricular arrhythmias. Circ Cardiovasc imaging. 2012;5:12–20.

4.2.5 Biomarkers

S4.2.5-1.	 Ahmad T, Fiuzat M, Neely B, et al. Biomarkers of myocardial stress and fibrosis as predictors of mode of death in patients with chronic heart failure. JACC Heart Fail. 2014;2:260–8. S4.2.5-2.	 Scott PA, Barry J, Roberts PR, et al. Brain natriuretic peptide for the prediction of sudden cardiac death and ventricular arrhythmias: a meta-analysis. Eur J Heart Fail. 2009;11:958–66. S4.2.5-3.	 Levine YC, Rosenberg MA, Mittleman M, et al. B-type natriuretic peptide is a major predictor of ventricular tachyarrhythmias. Heart Rhythm. 2014;11:1109–16. S4.2.5-4.	 Berger R, Huelsman M, Strecker K, et al. B-type natriuretic peptide predicts sudden death in patients with chronic heart failure. Circulation. 2002;105:2392–7. S4.2.5-5.	 Korngold EC, Januzzi JL Jr, Gantzer ML, et al. Amino-terminal pro- B-type natriuretic peptide and high-sensitivity C-reactive protein as predictors of sudden cardiac death among women. Circulation. 2009;119:2868–76. S4.2.5-6.	 Patton KK, Sotoodehnia N, DeFilippi C, et al. N-terminal pro-B-type natriuretic peptide is associated with sudden cardiac death risk: the Cardiovascular Health Study. Heart Rhythm. 2011;8:228–33. S4.2.5-7.	 Hussein AA, Gottdiener JS, Bartz TM, et al. Cardiomyocyte injury

assessed by a highly sensitive troponin assay and sudden cardiac death in the community: the Cardiovascular Health Study. J Am Coll Cardiol. 2013;62:2112–20.

4.2.6 Genetic Considerations in Arrhythmia Syndromes

S4.2.6-1.	 Andreasen C, Refsgaard L, Nielsen JB, et al. Mutations in genes

encoding cardiac ion channels previously associated with sudden

Downloaded from http://ahajournals.org by on October 7, 2026